133.66
price up icon0.69%   0.91
after-market After Hours: 130.99 -2.67 -2.00%
loading
Neurocrine Biosciences Inc stock is traded at $133.66, with a volume of 510.04K. It is up +0.69% in the last 24 hours and up +6.25% over the past month. Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$132.75
Open:
$133.275
24h Volume:
510.04K
Relative Volume:
0.45
Market Cap:
$13.23B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
45.31
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
+0.13%
1M Performance:
+6.25%
6M Performance:
-9.43%
1Y Performance:
-8.10%
1-Day Range:
Value
$133.10
$134.13
1-Week Range:
Value
$131.12
$135.70
52-Week Range:
Value
$84.23
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Name
Neurocrine Biosciences Inc
Name
Phone
(858) 617-7600
Name
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Employee
1,800
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
NBIX's Discussions on Twitter

Compare NBIX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
133.66 13.14B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
153.45 67.31B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.74 45.95B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.75 43.35B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.58 18.68B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
305.61 13.44B 2.99B 1.21B 1.13B 25.06

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-21-25 Initiated Truist Buy
Jul-10-25 Initiated Goldman Buy
Apr-15-25 Upgrade Needham Hold → Buy
Apr-14-25 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-11-25 Initiated Deutsche Bank Hold
Oct-10-24 Resumed Raymond James Outperform
Aug-29-24 Upgrade Piper Sandler Neutral → Overweight
Apr-24-24 Upgrade Wells Fargo Equal Weight → Overweight
Dec-13-23 Resumed Citigroup Neutral
Dec-12-23 Initiated Deutsche Bank Buy
Oct-24-23 Resumed Cantor Fitzgerald Overweight
Aug-21-23 Reiterated Mizuho Neutral
Jul-24-23 Upgrade SVB Securities Market Perform → Outperform
Jul-06-23 Upgrade BMO Capital Markets Underperform → Market Perform
May-04-23 Upgrade Guggenheim Neutral → Buy
Mar-30-23 Upgrade Canaccord Genuity Hold → Buy
Mar-03-23 Upgrade Evercore ISI In-line → Outperform
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-14-22 Downgrade Evercore ISI Outperform → In-line
Oct-11-22 Initiated UBS Buy
Sep-26-22 Initiated Wells Fargo Equal Weight
Jun-06-22 Resumed Jefferies Buy
Mar-03-22 Downgrade Piper Sandler Overweight → Neutral
Feb-25-22 Upgrade Goldman Neutral → Buy
Jan-18-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-21 Initiated BMO Capital Markets Underperform
Nov-17-21 Upgrade JP Morgan Neutral → Overweight
Oct-14-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-23-21 Resumed Needham Hold
Aug-06-21 Downgrade Canaccord Genuity Buy → Hold
May-18-21 Resumed Goldman Neutral
May-06-21 Upgrade Barclays Equal Weight → Overweight
Feb-02-21 Initiated Raymond James Outperform
Sep-30-20 Initiated The Benchmark Company Hold
Aug-04-20 Downgrade JP Morgan Overweight → Neutral
Jun-29-20 Downgrade Goldman Buy → Neutral
Jun-09-20 Initiated Wedbush Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-27-20 Initiated Barclays Equal Weight
Feb-24-20 Initiated William Blair Outperform
Feb-06-20 Initiated Mizuho Neutral
Feb-05-20 Reiterated H.C. Wainwright Buy
Dec-13-19 Downgrade Credit Suisse Outperform → Neutral
Aug-07-19 Initiated RBC Capital Mkts Outperform
Jul-16-19 Initiated Oppenheimer Outperform
Jun-05-19 Initiated Guggenheim Neutral
May-21-19 Initiated Credit Suisse Outperform
Apr-22-19 Upgrade JP Morgan Neutral → Overweight
Apr-12-19 Initiated Evercore ISI Outperform
Feb-06-19 Reiterated BofA/Merrill Buy
Jan-23-19 Downgrade JP Morgan Overweight → Neutral
Dec-13-18 Initiated Goldman Buy
Nov-21-18 Initiated Canaccord Genuity Buy
View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

pulisher
09:00 AM

What analysts say about Neurocrine Biosciences Inc. stockDynamic investment opportunities - Autocar Professional

09:00 AM
pulisher
10:00 AM

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

10:00 AM
pulisher
08:07 AM

Neurocrine Bio. stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Canada

08:07 AM
pulisher
Jul 22, 2025

What drives Neurocrine Biosciences Inc. stock priceAccelerated investment success - Autocar Professional

Jul 22, 2025
pulisher
Jul 21, 2025

Neurocrine Biosciences Inc. Stock Analysis and ForecastBreakthrough profits - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Truist Securities Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

Lobbying Update: $890,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Truist Securities initiates Neurocrine Bio stock with Buy rating on Crenessity potential - Investing.com Canada

Jul 21, 2025
pulisher
Jul 21, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Now Covered by Truist Financial - MarketBeat

Jul 21, 2025
pulisher
Jul 20, 2025

Is Neurocrine Biosciences Inc. a good long term investmentExplosive capital gains - Autocar Professional

Jul 20, 2025
pulisher
Jul 18, 2025

Daily Turnover | The turnover of Neurocrine Biosciences on 7/18 was $100.31 Million, Ranking 820 - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - simplywall.st

Jul 18, 2025
pulisher
Jul 17, 2025

Neurocrine Biosciences’ NBI-921352 Study: A Potential Game-Changer for SCN8A-DEE Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 16, 2025

Lobbying Update: $80,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.

Jul 16, 2025
pulisher
Jul 16, 2025

Neurocrine reports positive results from Crenessity trial - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Neurocrine Biosciences shares rise 2.09% after-hours after presenting new analysis on CAH treatment. - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Neurocrine shares new one-year data from trial of Crenessity for CAH - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Groundbreaking AI Research Exposes Lifelong Treatment Challenges for Rare CAH Patients - Stock Titan

Jul 15, 2025
pulisher
Jul 15, 2025

Neurocrine shares registry data showing CAH treatment challenges - StreetInsider

Jul 15, 2025
pulisher
Jul 15, 2025

Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 - PR Newswire

Jul 15, 2025
pulisher
Jul 15, 2025

New weight reduction data for Crenessity presented by Neurocrine - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

Wedbush Raises Price Target on Neurocrine Biosciences to $137 From $130, Keeps Outperform Rating - MarketScreener

Jul 15, 2025
pulisher
Jul 14, 2025

What makes Neurocrine Biosciences Inc. stock price move sharplyMassive Upside Selection - beatles.ru

Jul 14, 2025
pulisher
Jul 14, 2025

NBIX : Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

Endometriosis Market to Reach New Heights in Growth by 2034, - openPR.com

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences CRENESSITY Shows Clinically Meaningful Weight Loss And Insulin Resistance Improvement In Adults And Children With CAH In Phase 3 Trials, Presented At ENDO 2025 - 富途牛牛

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine presents one-year data showing weight improvements with CRENESSITY - StreetInsider

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting - Eastern Progress

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine presents one-year CRENESSITY data at ENDO 2025 conference - StreetInsider

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025 - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences: CRENESSITY's Breakthrough in CAH Positions NBIX for Sustained Growth - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine reports positive results from Crenessity trial (NBIX) - Seeking Alpha

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine reports positive one-year data for CAH treatment By Investing.com - Investing.com India

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine presents one-year data from study of Crenessity - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

CRENESSITY's Groundbreaking CAH Data Positions Neurocrine Biosciences for Dominance in a High-Impact Market - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine reports positive one-year data for CAH treatment - Investing.com

Jul 14, 2025
pulisher
Jul 14, 2025

New Clinical Data: CRENESSITY Achieves Breakthrough 30% Steroid Reduction in Adult CAH Treatment - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 - PR Newswire

Jul 14, 2025
pulisher
Jul 13, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Given New $174.00 Price Target at UBS Group - MarketBeat

Jul 13, 2025
pulisher
Jul 11, 2025

Neurocrine Biosciences (NBIX) CSO Onyia sells $7.8m in stock By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 11, 2025

Neurocrine Biosciences (NBIX) CSO Onyia sells $7.8m in stock - Investing.com Australia

Jul 11, 2025

Neurocrine Biosciences Inc Stock (NBIX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$305.61
price up icon 2.59%
drug_manufacturers_specialty_generic RDY
$14.60
price up icon 1.32%
$9.37
price up icon 1.41%
$15.02
price up icon 0.60%
$16.58
price up icon 1.78%
Cap:     |  Volume (24h):